<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03691623</url>
  </required_header>
  <id_info>
    <org_study_id>EDP 938-101</org_study_id>
    <nct_id>NCT03691623</nct_id>
  </id_info>
  <brief_title>A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model</brief_title>
  <official_title>A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered EDP-938 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enanta Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>hVIVO Services Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Enanta Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomised, Phase 2a, double-blind, placebo-controlled study to evaluate the safety,
      pharmacokinetics and antiviral activity of multiple doses of orally administered EDP-938 in
      healthy subjects infected with RSV-A Memphis 37b. This study is designed to compare the
      antiviral effect of EDP-938 compared to a placebo control in the respiratory syncytial virus
      challenge model.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 17, 2018</start_date>
  <completion_date type="Actual">October 18, 2019</completion_date>
  <primary_completion_date type="Actual">September 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in viral load measurements</measure>
    <time_frame>Post initial dose of EDP-938 up to Day 12</time_frame>
    <description>Area under the curve for RSV viral load as measured by RT-qPCR assay from the first viral load measurement post initial dose of EDP-938 or placebo through day 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of baseline symptoms</measure>
    <time_frame>Innoculation through Day 12</time_frame>
    <description>Change of baseline symptoms post initial dose of EDP-938 or placebo through Day 12</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">179</enrollment>
  <condition>RSV Infection</condition>
  <arm_group>
    <arm_group_label>EDP-938 Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will take EDP-938 Dose 1 oral suspension for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP-938 Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will take EDP-938 Dose 2 oral suspension for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will take matching placebo oral suspension for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP-938 Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will take EDP-938 Dose 3 oral suspension for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP-938 Arm E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will take EDP-938 Dose 4 oral suspension for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm F</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will take matching placebo oral suspension for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP-938 Dose 1</intervention_name>
    <description>Oral suspension for 5 days</description>
    <arm_group_label>EDP-938 Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP-938 Dose 2</intervention_name>
    <description>Oral suspension for 5 days</description>
    <arm_group_label>EDP-938 Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral suspension for 5 days</description>
    <arm_group_label>Placebo Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP-938 Dose 3</intervention_name>
    <description>Oral suspension for 5 days</description>
    <arm_group_label>EDP-938 Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP-938 Dose 4</intervention_name>
    <description>Oral suspension for 5 days</description>
    <arm_group_label>EDP-938 Arm E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral suspension for 5 days</description>
    <arm_group_label>Placebo Arm F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  An informed consent document signed and dated by the subject.

          -  Age 18 to 55 years, inclusive.

          -  In good health with no history of major medical conditions

          -  A total body weight ≥ 50 kg and Body Mass Index (BMI) ≥ 18 kg/m2 and ≤ 30kg/m2

        Exclusion Criteria:

          -  Pregnant or nursing females

          -  Acute or chronic medical illness

          -  Abnormal lung function

          -  Positive for HIV, active hepatitis A, B or C test

          -  Nose or nasopharynx abnormalities

          -  Receipt of any investigational drug within 3 months prior to the planned date of viral
             challenge/first dose of study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enanta Pharmaceuticals, Inc</last_name>
    <role>Study Director</role>
    <affiliation>Enanta Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>hVIVO Services Limited (hVIVO)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>September 28, 2018</study_first_submitted>
  <study_first_submitted_qc>September 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2018</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>challenge study</keyword>
  <keyword>RSV</keyword>
  <keyword>antiviral</keyword>
  <keyword>RSV-A Memphis 37b</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

